Key result
Combined LAA and ASD closure linked to ~67% fewer thromboembolic events versus ASD closure alone.
Why the study?
The safety and efficacy of simultaneous transcatheter LAA and ASD closure compared with ASD closure alone in a real-world cohort of patients with concurrent ASD and AF required evaluation.
Does simultaneous transcatheter left atrial appendage and atrial septal defect closure reduce thromboembolic and bleeding events compared to atrial septal defect closure alone in patients with concurrent atrial septal defect and atrial fibrillation?
Cohort (n=158)
Open-label
Yes
Does simultaneous transcatheter left atrial appendage and atrial septal defect closure reduce thromboembolic and bleeding events compared to atrial septal defect closure alone in patients with concurrent atrial septal defect and atrial fibrillation?
Answers are grounded in this paper and cite their sources.
In a propensity-matched cohort of patients with concurrent ASD and AF, simultaneous transcatheter LAA and ASD closure significantly reduced long-term risks of thromboembolic and bleeding events compared to ASD closure alone with oral anticoagulation, though it carried a 3.8% risk of perioperative cardiac tamponade.
Objectives To evaluate the safety and efficacy of simultaneous transcatheter left atrial appendage (LAA) and atrial septal defect (ASD) closure versus ASD closure alone in a real-world cohort of patients with concurrent ASD and atrial fibrillation (AF). Methods Between January 2016 and June 2026, 289 ASD and AF patients were assigned to simultaneous LAA and ASD closure or the conventional ASD closure alone group based on clinical decision-making and anatomical suitability. To reduce potential confounding bias between groups, propensity score matching (PSM) was performed using 1:1 nearest-neighbor matching. The perioperative, 30 d, 90 d, and 180 d safety and efficacy of the two groups were assessed, and then the embolism, bleeding, and other complications were recorded at outpatient telephone visits every year, and the results of the follow-up. Results A total of 79 ASD with AF patients were included in the simultaneous occlusion group, of whom 27 received LACBES and 52 received LAmbre LAA occluders, while 79 ASD with AF patients who underwent ASD closure alone were matched by PSM. In the simultaneous occlusion group, three patients developed cardiac tamponade at 8, 20, and 30 h after occlusion, respectively. During follow-up, the simultaneous occlusion group had a lower incidence of bleeding events (2.53% vs. 13.92%, P = 0.017). No statistically significant difference was observed in the incidence of embolism events between the two groups (5.06% vs. 15.19%, P = 0.062). Compared with ASD closure alone, simultaneous LAA + ASD occlusion was associated with a lower risk of all thromboembolic events (HR = 0.333, 95% CI: 0.125–0.888, P = 0.0455) and a significantly lower risk of bleeding events (HR = 0.182, 95% CI: 0.061–0.539, P = 0.0126). Conclusion In this real-world observational cohort, simultaneous percutaneous LAA and ASD closure in carefully selected patients was associated with favorable long-term safety and effectiveness, particularly in reducing thromboembolic events and bleeding events risk compared with ASD closure alone.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cohort in Concurrent congenital atrial septal defect and atrial fibrillation (n=158). Simultaneous transcatheter left atrial appendage and atrial septal defect closure vs. Transcatheter atrial septal defect closure alone was evaluated on All thromboembolic events (ischemic stroke, transient ischemic attack, systemic thromboembolism) (HR 0.333, 95% CI 0.125-0.888, p=0.0455). Simultaneous transcatheter LAA and ASD closure reduced thromboembolic and bleeding events versus ASD closure alone in patients with ASD and AF.
Synapse has enriched 10 related papers. Consider them for comparative context: